Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2015-04-29 Regulatory Filings
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release dated April 29, 2015, from Theradiag announcing the publication of a study in the *Journal of Crohn's and Colitis* regarding the monitoring of infliximab and C-Reactive Protein (CRP) to predict loss of response in Inflammatory Bowel Disease (IBD) patients. This announcement details scientific findings and their implications for patient care, rather than presenting official financial results (like ER or 10-K), management changes (MANG), or regulatory filings. It is a general corporate announcement related to the company's diagnostic products and research validation. Since it is not a standard financial report, a specific regulatory filing, or a management/board update, it falls best under the general category for corporate news releases that don't fit elsewhere, which is Regulatory Filings (RNS), as it is a public announcement of a significant development. However, given the context of a diagnostic company announcing a study validation, it is a form of Investor Relations communication. Since RNS is the fallback for miscellaneous regulatory/corporate announcements, and this is not a specific financial report (like ER, IR, 10-K) or a specific corporate action (like DIV, CAP, MANG), RNS is the most appropriate classification among the provided options for a general press release about scientific validation.
2015-04-29 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly states the total number of shares and voting rights as of a specific date (March 31, 2015) and references French regulatory articles (AMF General Regulation). This type of mandatory disclosure regarding the total share capital and voting rights is a specific corporate action announcement. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with an announcement related to capital structure changes or a specific regulatory filing that details share count. Given the options, this announcement about the total number of shares and voting rights fits best under 'Share Issue/Capital Change' (SHA) as it directly relates to the capital structure, or potentially 'Regulatory Filings' (RNS) if it were a generic filing. However, since it details the current state of the capital base, SHA is the most precise fit among the specific categories provided, as it reflects the current state of the share base.
2015-04-02 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 25, 2015, announcing that THERADIAG obtained CE marking for its 10th biotherapy monitoring test (Stelara®). It details a product development achievement and includes quotes from management and boilerplate information about the company. This type of announcement, focusing on a specific operational or product milestone rather than comprehensive financial results (10-K, IR, ER) or management changes (MANG), is best classified as a general Regulatory Filing or an announcement that doesn't fit the highly specific categories. Since it is an announcement of a regulatory/product achievement (CE marking), and not a formal financial report, it falls under the general 'Regulatory Filings' (RNS) category, as it is a specific, non-financial regulatory update that doesn't match other codes like DIV, CAP, or DIRS. Given the context of a press release announcing a regulatory approval (CE marking), RNS is the most appropriate fallback.
2015-03-25 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated March 25, 2015, announcing that the company, Theradiag, has received CE marking for a new biotherapy monitoring test (Stelara® monitoring test). It details the significance of this product addition to their LISA TRACKER range and includes quotes from the CEO and boilerplate information about the company and investor contacts. This type of announcement, which communicates a specific business development, product approval, or material event that is not a standard periodic financial report (like 10-K or IR) or a formal regulatory filing like a Director's Dealing or Major Shareholding notification, fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad announcement of a material event to the market, often disseminated via regulatory news services. It is too specific for a general 'Capital/Financing Update' (CAP) and is not a transcript, earnings release, or formal report.
2015-03-25 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 23, 2015, announcing the company THERADIAG's strong presence and four presentations at the JFHOD 2015 congress regarding their LISA TRACKER biotherapy monitoring tests. It details the content of oral and poster presentations and includes quotes from management and contact information for investor relations and press. This format—a news announcement about company activities, scientific findings, or participation in industry events, rather than a formal regulatory filing (like 10-K, IR, or ER)—best fits the category for general corporate communications or investor updates. Since it is not a formal financial report, a management discussion (MDA), or a specific regulatory announcement like a dividend or share transaction, it falls under the general category of Investor Presentation (IP) or Regulatory Filings (RNS). Given that it is a detailed summary of scientific presentations intended for investors and the public, 'Investor Presentation' (IP) is a strong fit, although it is structured as a press release. However, looking closely at the definitions, it is an announcement *about* scientific findings presented at a conference, which is often distributed as a press release. It is not a formal presentation deck (IP) itself, nor is it a transcript (CT). It is a general corporate update. Since it doesn't fit the highly specific financial report categories, the most appropriate general category for corporate news updates that aren't formal filings is often RNS, but given the focus on scientific/investor-facing content, IP is considered. Since it is a press release summarizing scientific data presented at a conference, and not a formal presentation deck, the best fit among the provided options for this type of corporate communication summarizing external events is often RNS (Regulatory Filings/General Announcement) or potentially IP if interpreted broadly as investor material. Given the content is a summary of scientific data presented at a conference, which is a common type of investor communication, I will classify it as Investor Presentation (IP), as it serves to inform investors about scientific validation, even though it is formatted as a press release.
2015-03-23 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release from Theradiag announcing its strong presence and presentations at the 2015 JFHOD meeting. It details the scientific findings and the relevance of their LISA TRACKER tests, quoting the CEO. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about participation in a medical conference and the associated scientific data presented there. Since it is a general announcement about company activities and scientific validation, and does not fit the specific categories like AGM-R, ER, IR, or CT, it falls best under the general Regulatory Filings/Announcements category (RNS) as a miscellaneous corporate communication, although it is primarily a press release about a scientific event.
2015-03-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.